Inmune Bio, Inc. 8-K

What Happened

• On January 27, 2026, Inmune Bio, Inc. (INMB) announced via press release that it issued a shareholder letter providing updates on prior and future operations. The press release and shareholder letter are included as Exhibit 99.1 to the 8-K.
• The company filed this disclosure under Item 7.01 (Regulation FD disclosure) and furnished the related exhibit under Item 9.01. The company states the information is being furnished — not “filed” — and thus is not subject to certain liabilities under the Exchange Act and Securities Act.

Key Details

• Date of disclosure: January 27, 2026.
• Documents provided: press release announcing a shareholder letter; Exhibit 99.1 attached to the 8-K.
• Filing status: information furnished (Regulation FD disclosure) — not considered “filed” for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
• Items reported: Item 7.01 (Regulation FD disclosure) and Item 9.01 (exhibits).

Why It Matters

• Investors should review the shareholder letter and press release for operational updates directly from management; these materials may include progress on programs, strategy, or planning that could affect future expectations.
• Because the materials are furnished (not filed), the company is signaling compliance with public disclosure rules while limiting certain legal liabilities tied to formal “filed” disclosures.
• This 8-K does not report earnings, executive changes, or transaction announcements — it’s a company communication providing updates rather than a financial or corporate-action filing.